PROCYTE CORPORATION INTRODUCES NEOVA® THERAPY DUAL ACTION
LOTION
GHK Copper Peptide Complex® + Retinol
Redmond, Wash.—March 9, 2004—ProCyte Corporation (OTCBB: PRCY.OB),
announces the introduction of Neova® Therapy Dual Action
Lotion which uses advanced nanoencapsulation technology to stabilize the
combination of two anti-aging powerhouses, GHK Copper Peptide Complex®
micronutrition and Retinol, into an intensive lightweight lotion.
Copper is an essential component for collagen and elastin production,
while providing a potent antioxidant defense against free radicals.
Clinical studies have demonstrated the many benefits of GHK:Cu including
decreased fine lines and wrinkles, decreased skin blotchiness and an
increase in skin firmness and tone – all without irritation! Retinol is
a well known and extensively studied skincare ingredient.
Looking good is a concern for all, especially aging baby-boomers. The aging
process and photodamage cause the skin to thin and lines and wrinkles
begin to develop. The body becomes slower to produce collagen, elastin
and glycosaminoglycans. Age spots appear and skin becomes dull and
lifeless as cell renewal slows and the skin’s ability to retain moisture
is diminished.
Scientific Studies have shown that:
·
Copper plays an essential role in skin health by helping restore the skin’s ability to recover
from damage.
·
Copper is a powerful
collagen and elastin promoter, both important for firm skin.
·
Copper works as an
antioxidant by stimulating superoxide dismutase activity.
·
Copper is important in the
production of glycosaminoglycans (the cement that bonds tissue
components together).
·
Copper-dependent enzymes
increase the benefits of natural tissue building processes.
Neova® Therapy Dual Action Lotion:
·
Nourishes skin with
clinically proven GHK Copper Peptide Complex® technology.
·
Retinol (pure Vitamin A)
is gradually released to the skin, minimizing potential for irritation.
·
Immediately helps to
improve skin tone and texture.
·
Clinical studies using GHK Copper Peptide
show a reduction in fine lines and
wrinkles.
·
Aloe Vera Gel and Vitamin
E soothe and protect.
·
Leaves skin looking
smooth and radiant.
“We are very excited about this product introduction into the physician
market. Once again ProCyte is on the forefront of skin care product
development with this new product,” said Jack Clifford, President and
CEO. “This product is the first of a series of new GHK copper peptide
combination products being developed by ProCyte and covered by our new
pending patent applications.”
Neova® Therapy Dual Action Lotion is available in a 1 oz. bottle and can be
purchased through leading dermatologists and plastic surgeons offices or
on line through leading medical skin care websites.
ProCyte Corporation develops and markets products based on its patented,
clinically proven copper peptide technology for skin health, hair care
and wound care. The Company sells directly to dermatologists, plastic
and cosmetic surgeons, spas and through licenses with strategic partners
into the consumer market, including its long-term worldwide license
agreement with Neutrogena®, a Johnson & Johnson company.
ProCyte’s products include Neova®, VitalCopper™, Simple
Solutions® and
AquaSanté® Skin Care products; Complex Cu3®
Post-Procedure Skin Care; GraftCyte® Hair Transplant Care;
and Tricomin® Advanced Care for Thinning Hair. The Company
also has the exclusive distribution rights for Cutanix Corporation’s
Quadrinone® technology for medical and spa markets in the
U.S., Canada and Puerto Rico. Additional information is available by
visiting the Company’s website at www.procyte.com and
www.vitalcopper.com.
###
This release may contain forward-looking statements relating to the
research, development, commercialization, production, marketing and
distribution of the Company's products and future operating results,
which are subject to certain risks and uncertainties that could cause
actual results to differ materially from those projected.
The words “believe,” “expect,” “intend,” “anticipate,” variations of such
words, and similar expressions identify forward-looking statements, but their absence does not mean
that the statement is not forward-looking. These statements are not
guarantees of future performance and are subject to certain risks,
uncertainties and assumptions that are difficult to predict. Factors
that could affect the Company’s actual results include its ability to
develop, commercialize and produce new products; the market acceptance
of existing and potential future products; the availability, cost and
timely delivery of materials and services from and performance of
third-party suppliers, manufacturers, distributors, licensees and other
collaborative partners; the satisfaction of regulatory requirements, and
the receipt, timing, terms and conditions of required regulatory
approvals. Reference is made to the Company’s Annual Report on Form
10-K for the year ended December 31, 2002 and its latest Quarterly
Report on Form 10-Q filed with the Securities and Exchange Commission
for a more detailed description of such factors. Readers are cautioned
not to place undue reliance on these forward-looking statements, which
speak only as of the date of this release. The Company undertakes no
obligation to publicly update any forward-looking statement to reflect
new information, events or circumstances after the date of this release
or to reflect the occurrence of unanticipated events. |
